Free Trial
NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

4D Molecular Therapeutics logo
$6.53 -0.21 (-3.12%)
Closing price 08/26/2025 04:00 PM Eastern
Extended Trading
$6.52 -0.01 (-0.15%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

Key Stats

Today's Range
$6.43
$6.83
50-Day Range
$3.71
$7.27
52-Week Range
$2.23
$17.41
Volume
908,342 shs
Average Volume
2.60 million shs
Market Capitalization
$304.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.40
Consensus Rating
Moderate Buy

Company Overview

4D Molecular Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

FDMT MarketRank™: 

4D Molecular Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 734th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    4D Molecular Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about 4D Molecular Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 4D Molecular Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 4D Molecular Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    4D Molecular Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about 4D Molecular Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.84% of the float of 4D Molecular Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    4D Molecular Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 4D Molecular Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    4D Molecular Therapeutics does not currently pay a dividend.

  • Dividend Growth

    4D Molecular Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.84% of the float of 4D Molecular Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    4D Molecular Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 4D Molecular Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing.
  • News Sentiment

    4D Molecular Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    10 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of 4D Molecular Therapeutics is held by insiders.

  • Percentage Held by Institutions

    99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 4D Molecular Therapeutics' insider trading history.
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FDMT Stock News Headlines

4DMT to Participate in Upcoming Investor Conferences
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Chardan Capital Issues Pessimistic Outlook for FDMT Earnings
Q3 Earnings Estimate for FDMT Issued By Leerink Partnrs
HC Wainwright Analysts Decrease Earnings Estimates for FDMT
4DMT Announces New Employment Inducement Grants
See More Headlines

FDMT Stock Analysis - Frequently Asked Questions

4D Molecular Therapeutics' stock was trading at $5.57 on January 1st, 2025. Since then, FDMT stock has increased by 17.2% and is now trading at $6.53.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its earnings results on Monday, August, 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by $0.10. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative trailing twelve-month return on equity of 40.15%.

4D Molecular Therapeutics (FDMT) raised $101 million in an IPO on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Top institutional shareholders of 4D Molecular Therapeutics include BVF Inc. IL (9.91%), Federated Hermes Inc. (3.60%), Geode Capital Management LLC (1.98%) and Raymond James Financial Inc. (0.98%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily and Robert Young Kim.
View institutional ownership trends
.

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
8/11/2025
Today
8/27/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FDMT
CIK
1650648
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$44.00
Low Price Target
$6.00
Potential Upside/Downside
+365.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$160.87 million
Net Margins
-594,375.81%
Pretax Margin
-594,375.75%
Return on Equity
-40.15%
Return on Assets
-36.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.75
Quick Ratio
8.75

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
7,623.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.01 per share
Price / Book
0.72

Miscellaneous

Outstanding Shares
46,700,000
Free Float
42,219,000
Market Cap
$304.95 million
Optionable
Optionable
Beta
2.83

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:FDMT) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners